and the Biodiesel blend in Diesel Mandate has made to 7% or B7 on May 8, 2017 since CPO became over supply. 1.2 Revenues from sales of by-products to total revenue for the 3rd quarter of 2017 and 2016
period and quarterly, principal repayment: Baht 80.4 million/period (the last repayment will be made for remaining principal) at a fixed rate per annum Page 7 of 7 FPT - Long term loan from BBL was of
. However, the company's research and development team has continued to develop the products made of natural rubber to have an equal of level of the product quality with the competitors. The market share of
, Thailand, made the following resolutions pertaining to the important agenda as follows: 1) Liquidation of Advanced Biochemical Europe Resolved to approve the liquidation of Advanced Biochemical Europe
Board of Directors No. 2/2018 of the Company held on 27 February 2018, has resolved significant matters as follows: Reference is made to the Clarification Letter regarding the Board of Directors’ opinion
TRANSLATED VERSION As of August 27, 2014 Readers should be aware that only the original Thai text has legal force and that this English translation is strictly for reference. 37 Notification of the Capital Market Supervisory Board No. TorThor. 35/2556 Re: Standard Conduct of Business, Management Arrangement, Operating Systems, and Providing Services to Clients of Securities Companies and Derivatives Intermediaries _____________________________ By virtue of Section 16/6 and Section 113 of the Sec...
outbound product which is a debt instrument approved to be offered for sale in a debt issuance program by the regulator under (2) for each specific investor (tailor-made product); (c) any case other than (a
an outbound product which is a debt instrument approved to be offered for sale in a debt issuance program by the regulator under (2) for each specific investor (tailor-made product); (c) any case other
an outbound product which is a debt instrument approved to be offered for sale in a debt issuance program by the regulators under (2) for each specific investor (tailor-made product); (c) any case
is a debt instrument approved to be offered for sale in a debt issuance program by the regulators under (2) for each specific investor (tailor-made product); (c) any case other than (a) and (b), being